Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics

Journal of Infectious Diseases

Volumn 191, Issue 8, 2005, Pages 1272-1279

  Orscheln, Rachel C ^a   Johnson, Dwight R ^b   Olson, Stephen M ^a   Presti, Rachel M ^a   Martin, Judith M ^c   Kaplan, Edward L ^b   Storch, Gregory A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; VANCOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; GENE SEQUENCE; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES;

ADULT; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; EVOLUTION, MOLECULAR; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; SEQUENCE ANALYSIS, DNA; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TIME FACTORS;

EID: 17044430108     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428856     Document Type: Article

References (37)

1. Scheid WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9:1-9.
2. Burkhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990; 27:162-70.
3. Stahlmann R, Merker HJ, Hinz N, et al. Ofloxacin in juvenile non-human primates and rats: arthropathia and drug plasma concentrations. Arch Toxicol 1990; 64:193-204.
4. Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse: morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 1995; 28:59-64.
5. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163:1279-85.
6. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43:1310-3.
7. Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998;41:420-1.
8. Richter SS, Diekema DJ, Heilmann KP, et al. Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis 2003; 36:380-3.
9. Van SS, Fox ML, Holland SM, Stock F, Gill VJ, Fedorko DP. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and porC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 2000; 44:3196-8.
10. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996; 40:2252-7.
11. Janior C, Zeller V, Kitzis M, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40:2760-4.
12. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone Trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 1996; 40:2691-7.
13. Bast DJ, Low DE, Duncan CL, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000; 44:3049-54.
14. Alonso R, Galimand M, Courvalin P. parC mutation conferring cip-rofloxacin resistance in Streptococcus pyogenes BM4513. Antimicrob Agents Chemother 2002; 46:3686-7.
15. Fischetti VA. Group A strain directory: M type 1 to 67. Available at: http://www.rockefeller.edu/vaf/mtypedir.htm. Accessed 15 March 2004.
16. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200-6.
17. NCCLS. Performance standards for antimicrobial disk susceptibility testing-approved standard [NCCLS document M2-A8]. 8th ed. Wayne, PA: NCCLS, 2003.
18. Johnson DR, Kaplan EL, Sramek J, et al. Laboratory diagnosis of group A streptococcal infections. Geneva: World Health Organization, 1996.
19. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996; 34:953-8.
20. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166: 374-82.
21. Tyrrell GJ, Lovgren M, Forwick B, Hoe NP, Musser JM, Talbot JA. M types of group A streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999. J Clin Microbiol 2002; 40:4466-71.
22. Kaplan EL, Johnson DR, Rehder CD. Recent changes in group A streptococcal serotypes from uncomplicated pharyngitis: a reflection of the changing epidemiology of severe group A infections? J Infect Dis 1994; 170:1346-7.
23. Anthony BF, Kaplan EL, Wannamaker LW, Chapman SS. The dynamics of streptococcal infections in a defined population of children: serotypes associated with skin and respiratory infections. Am J Epidemiol 1976; 104:652-66.
24. Hoe NP, Fullerton KE, Liu M, et al. Molecular genetic analysis of 675 group A streptococcus isolates collected in a carrier study at Lackland Air Force Base, San Antonio, Texas. J Infect Dis 2003; 188:818-27.
25. Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet 2001; 358: 1334-7.
26. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441-6.
27. Van JJ, Wu HM, Huang AH, Fu HM, Lee CT, Wu JJ. Prevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan. J Clin Microbiol 2000; 38:2475-9.
28. Bassetti M, Manno G, Collida A, et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 2000; 6:180-3.
29. Alos JI, Aracil B, Oteo J, Torres C, Gomez-Garces JL. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting. J Antimicrob Chemother 2000; 45:605-9.
30. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45:3334-40.
31. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999; 37:1727-31.
32. Bozdogan B, Appelbaum PC, Kelly LM, et al. Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe. Clin Microbiol Infect 2003; 9:741-5.
33. Gonzalez I, Georgiou M, Alcaide F, Balas D, Linares J, de la Campa AG. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 1998; 42:2792-8.
34. Ferrandiz MJ, Fenoll A, Linares J, De La Campa AG. Horizontal transfer of purC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:840-7.
35. Balsalobre L, Ferrándiz MJ, Linares J, Tubau F, de la Campa AG. The viridans streptococci are the donors in the horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2072-81.
36. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341:233-9.
37. Etienne M, Croisier D, Charles P, et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190:1472-5.